ZETIA (ezetimibe) is in a class of lipid-lowering compounds that selectively inhibits the intestinal absorption of cholesterol and related phytosterols.
ZETIA is indicated for the following:
ZETIA, administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hypercholesterolemia.
Combination therapy with HMG-CoA reductase inhibitors
ZETIA, administered in combination with an HMG-CoA reductase inhibitor, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hypercholesterolemia.
Homozygous Familial Hypercholesterolemia (HoFH)
The combination of ZETIA and atorvastatin or simvastatin, is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable.
ZETIA is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia.
Therapy with lipid-altering agents should be a component of multiple risk-factor intervention in individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lipid-altering agents should be used in addition to an appropriate diet (including restriction of saturated fat and cholesterol) and when the response to diet and other non-pharmacological measures has been inadequate.
Published Studies Related to Zetia (Ezetimibe)
Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo-
and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab
in subjects with hypercholesterolemia on background statin therapy. 
Low-density lipoprotein cholesterol (LDL-C) levels are significantly associated
with atherosclerotic cardiovascular disease (ASCVD) risk, and studies using
interventions that lower LDL-C levels have been shown to reduce the risk of ASCVD
events and mortality... This
study will also provide comparative efficacy, safety, and tolerability data
between evolocumab and ezetimibe when added to background atorvastatin therapy.
Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered
with extended-release niacin in hyperlipidemic patients. 
CONCLUSIONS: These results suggest that E/S+N improves lipoprotein particle
The effects of ezetimibe/simvastatin versus simvastatin monotherapy on platelet
and inflammatory biomarkers in patients with metabolic syndrome. 
In a randomized, double-blind, crossover study of 15 aspirin-naive patients (mean
age 48.8 ± 10.2 years) with the metabolic syndrome, statin monotherapy
(simvastatin 40 mg daily) was compared to combination therapy (simvastatin 40 mg
and ezetimibe 10 mg daily) on biomarkers of inflammation and platelet activity...
A comparison of efficacy and safety of an ezetimibe/simvastatin combination
compared with other intensified lipid-lowering treatment strategies in diabetic
patients with symptomatic cardiovascular disease. 
The low-density lipoprotein cholesterol (LDL-C) lowering efficacy of switching to
ezetimibe/simvastatin (EZ/S) 10/20 mg versus doubling the run-in statin dose (to
simvastatin 40 mg or atorvastatin 20 mg) or switching to rosuvastatin 10 mg in
subjects with cardiovascular disease (CVD) and diabetes was assessed...
Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce
low-density lipoprotein cholesterol in patients with heterozygous familial
hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a
phase 2 randomised controlled trial. 
hypercholesterolaemia... INTERPRETATION: REGN727 was well tolerated and achieved substantial further LDL-C
Clinical Trials Related to Zetia (Ezetimibe)
Pharmacokinetic Drug Interaction Between Ezetimibe and Tacrolimus After Single Dose Administration in Healthy Subjects [Completed]
Pharmacokinetic Drug Interaction Between Ezetimibe and Sirolimus After Single Dose Administration in Healthy Subjects [Completed]
Comparison of Ezetimibe Plus Simvastatin Versus Ezetimibe or Simvastatin Alone in Subjects With Primary Hypercholesterolemia (Study P03757)(COMPLETED) [Completed]
This is a multicenter, randomized, double blind; active-controlled parallel groups study
enrolling subjects with primary hypercholesterolemia. Subjects receive ezetimibe,
simvastatin, or the combination once daily for 8 weeks to determine the effect on
Assessment of Potential Interaction Between Ezetimibe and Rosuvastatin in Healthy Subjects With High Cholesterol (P03317)(COMPLETED) [Completed]
The purpose of this study is to obtain data of the coadministration of ezetimibe and
rosuvastatin to support the concomitant use of these two drugs in patients requiring
additional cholesterol-lowering management. Treatment is administered for 14 days.
Evaluation of Potential for Drug Interaction Between SCH 58235 (Ezetimibe) and Pitavastatin (Study P03962)(COMPLETED) [Completed]
This study was designed to evaluate the pharmacokinetic interaction and safety of
coadministration of SCH 58235 (ezetimibe) and pitavastatin in healthy Japanese adult male
subjects or adult male subjects having no obvious disease other than high cholesterol
Reports of Suspected Zetia (Ezetimibe) Side Effects
Pain in Extremity (31),
Drug Ineffective (20),
Back Pain (20), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Zetia has an overall score of 9. The effectiveness score is 8 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
Zetia review by 60 year old male patient
|Overall rating:|| || |
|Effectiveness:|| || Considerably Effective|
|Side effects:|| || No Side Effects|
|Condition / reason:|| || high cholestrol|
|Dosage & duration:|| || 10mg/day taken ongoing for the period of ongoing|
|Other conditions:|| || knee osteoartritis|
|Other drugs taken:|| || glucosamine, multivitamins|
|Benefits:|| || My target was to have the a cholestrol reduction from 240 to under 200. I did not want want to take statins because I am not comfortable with drugs that inhibit normal metabolic processes. Evolution is parsimonius, and inhibition of any enzyme is likely to be reflected as an adverse effect in a seemingly unrelated area. Also, I did not want to take red yeast rice, which basically is a non-phrmaceutical grade of a statin. I liked the physical mode of action of Zetia. Within 6 months of starting treatment, my total cholesterol was down from to 200 and my HDL went up from 45 to 58. |
|Side effects:|| || I did not experience any perceptible side effects.|
|Comments:|| || See treatment benefits above. I take my daily dose of Zetia shortly after having my breakfast.|
Page last updated: 2014-12-01